AU2017327383B2 - Method of reducing thyroid-associated side effects - Google Patents

Method of reducing thyroid-associated side effects Download PDF

Info

Publication number
AU2017327383B2
AU2017327383B2 AU2017327383A AU2017327383A AU2017327383B2 AU 2017327383 B2 AU2017327383 B2 AU 2017327383B2 AU 2017327383 A AU2017327383 A AU 2017327383A AU 2017327383 A AU2017327383 A AU 2017327383A AU 2017327383 B2 AU2017327383 B2 AU 2017327383B2
Authority
AU
Australia
Prior art keywords
optionally substituted
group
alkyl
days
followed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017327383A
Other languages
English (en)
Other versions
AU2017327383A1 (en
Inventor
Mark Erion
Bruce Ito
Brian Lian
Hiroko Masamune
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Viking Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Viking Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc, Viking Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of AU2017327383A1 publication Critical patent/AU2017327383A1/en
Application granted granted Critical
Publication of AU2017327383B2 publication Critical patent/AU2017327383B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017327383A 2016-09-16 2017-09-13 Method of reducing thyroid-associated side effects Active AU2017327383B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662396015P 2016-09-16 2016-09-16
US201662396025P 2016-09-16 2016-09-16
US62/396,015 2016-09-16
US62/396,025 2016-09-16
PCT/US2017/051410 WO2018053036A1 (en) 2016-09-16 2017-09-13 Method of reducing thyroid-associated side effects

Publications (2)

Publication Number Publication Date
AU2017327383A1 AU2017327383A1 (en) 2019-04-11
AU2017327383B2 true AU2017327383B2 (en) 2023-06-29

Family

ID=61619247

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017327383A Active AU2017327383B2 (en) 2016-09-16 2017-09-13 Method of reducing thyroid-associated side effects

Country Status (9)

Country Link
US (1) US20190255080A1 (cg-RX-API-DMAC7.html)
EP (1) EP3512523A4 (cg-RX-API-DMAC7.html)
JP (2) JP2019531346A (cg-RX-API-DMAC7.html)
KR (2) KR20240074912A (cg-RX-API-DMAC7.html)
CN (2) CN109922812A (cg-RX-API-DMAC7.html)
AU (1) AU2017327383B2 (cg-RX-API-DMAC7.html)
CA (1) CA3037146A1 (cg-RX-API-DMAC7.html)
MX (2) MX2019003032A (cg-RX-API-DMAC7.html)
WO (1) WO2018053036A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
AU2020267953A1 (en) * 2019-05-08 2021-11-18 Novartis Ag Anti-CD40 antibodies for use in treatment of T1DM and insulitis
RU2728261C2 (ru) * 2019-05-22 2020-07-28 Ирина Алексеевна Курникова Способ дифференциальной диагностики йоддефицитного и йодиндуцированного нарушения функции щитовидной железы у лиц, проживающих в регионах с йодным дефицитом
CA3147789A1 (en) * 2019-08-19 2021-02-25 Hepagene Therapeutics (HK) Limited Heterocyclic thr-.beta. receptor agonist compound and preparation method and use therefor
CN112457346B (zh) * 2019-08-19 2022-09-06 和博医药有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途
EP4019524A4 (en) * 2019-08-19 2024-01-03 Hepagene Therapeutics (HK) Limited HETEROCYCLIC THR-BETA RECEPTOR AGONIST COMPOUND, PREPARATION METHOD AND USE THEREOF
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
WO2026092581A1 (en) * 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
WO2017184811A1 (en) * 2016-04-22 2017-10-26 Metabasis Therapeutics, Inc. Thyroid hormone receptor agonist and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
MXPA04012497A (es) * 2002-07-04 2005-07-14 Zealand Pharma As Glp-1 y metodos para tratar la diabetes.
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20090232879A1 (en) * 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
WO2009089093A1 (en) * 2008-01-04 2009-07-16 Quatrx Pharmaceuticals Company Thyroid hormone receptor agonists
CN106344495A (zh) * 2008-12-22 2017-01-25 奥德纳米有限公司 用于治疗耳部病症的控制释放耳感觉细胞调节剂组合物
WO2018094265A2 (en) * 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
WO2017184811A1 (en) * 2016-04-22 2017-10-26 Metabasis Therapeutics, Inc. Thyroid hormone receptor agonist and use thereof

Also Published As

Publication number Publication date
BR112019005039A2 (pt) 2019-06-25
EP3512523A4 (en) 2020-05-06
AU2017327383A1 (en) 2019-04-11
KR20240074912A (ko) 2024-05-28
CN109922812A (zh) 2019-06-21
MX2019003032A (es) 2019-09-13
JP2019531346A (ja) 2019-10-31
WO2018053036A1 (en) 2018-03-22
KR20190060786A (ko) 2019-06-03
JP2022174261A (ja) 2022-11-22
NZ751857A (en) 2024-05-31
EP3512523A1 (en) 2019-07-24
JP7656574B2 (ja) 2025-04-03
US20190255080A1 (en) 2019-08-22
CN121695155A (zh) 2026-03-20
MX2023000887A (es) 2023-02-22
CA3037146A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
JP7656574B2 (ja) 甲状腺関連副作用を低下させる方法
JP2025016462A (ja) 多発性硬化症を処置するためのs1p受容体モジュレーター
AU2018280118B2 (en) Compositions for the treatment of fibrosis
JP2022510691A (ja) 線維症及び炎症の処置のための組成物
CA3044059A1 (en) Method of treating glycogen storage disease
US20100222376A1 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
JP2010535159A (ja) レオヌリンの使用およびその組成物
JPH06279397A (ja) アミノ酸系末梢神経障害改善剤
BR112019005039B1 (pt) Método de redução dos efeitos colaterais associados à tireoide
RU2850978C1 (ru) Применение агониста рецептора сфингозин-1-фосфата
KR20070102694A (ko) 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
JP2024512510A (ja) 置換芳香族化合物及びその医薬組成物
EA042390B1 (ru) Способ терапевтического лечения фиброза
JPH1135461A (ja) 睡眠障害の治療剤
HK1177423B (en) Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)